Business
Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results
RICHMOND HILL, ON / ACCESSWIRE / December 15, 2021 / Helix BioPharma Corp. (TSX:HBP), (" He...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix Biopharma Corp. Announces Fiscal 2022 First Quarter ResultsRICHMOND HILL, ON / ACCESSWIRE / December 15, 2021 / Helix BioPharma Corp. (TSX:HBP), (\" Helix \" or the \" Company \"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 first quarter results for the period ending October 31, 2021.OVERVIEWThe Company reported a net loss and total comprehensive loss for the three-month period ended October 31, 2021, of $1,813,000 (2020 - $222,000). Net loss and comprehensive loss for the three-month period ending October 31, 2020, included a gain from loss of control in Helix Immuno-Oncology S.A. (\"HIO\") of $2,162,000.Clinical developmentPhase I combination therapy study in lung cancer (LDOS001):Final clinical study report expected to be completed by the end of December 2021;Phase II combination therapy trial in lung cancer (LDOS003):Final clinical study report expected to be completed in March 2022 provided the Company settles a contractual disagreement with the clinical research organization engaged to oversee the study.The Company ceased patient enrolment into the trial in 2020 and proceeded to data analysis.As previously announced, the Company will not be advancing the randomized portion of the study without third-party partner funding. To date, no third-party partner has been identified.Phase Ib/II combination trial in pancreatic cancer (LDSOS006):On November 15, 2021, the Company applied for a revision to the clinical protocol to the U.S. Food and Drug Administration (\"FDA\").L-DOS47 immunotherapy chemo combination study in lung cancer:The Company engaged key opinion leaders on the feasibility and design of a possible immunotherapy chemo combination clinical study. The Company is not currently in a position to make a submission to the FDA regarding the potential clinical study.Clinical drug product strategic review:The Company hired biotechnology consults to assess the Company's drug product candidate with a focus on identifying value propositions and positioning strategies that would enable clinical adoption of L-DOS47. This engagement includes input from key opinion leaders on the positioning of possible combination therapies and the prioritization of current and/or any additional clini...